653 related articles for article (PubMed ID: 16997664)
1. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
; Gerstein HC; Yusuf S; Bosch J; Pogue J; Sheridan P; Dinccag N; Hanefeld M; Hoogwerf B; Laakso M; Mohan V; Shaw J; Zinman B; Holman RR
Lancet; 2006 Sep; 368(9541):1096-105. PubMed ID: 16997664
[TBL] [Abstract][Full Text] [Related]
2. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
[TBL] [Abstract][Full Text] [Related]
3. [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].
Scheen AJ
Rev Med Liege; 2006 Oct; 61(10):728-32. PubMed ID: 17209507
[TBL] [Abstract][Full Text] [Related]
4. [Experiences of the DREAM trial].
Fövényi J
Orv Hetil; 2006 Dec; 147(52):2523-6. PubMed ID: 17294577
[TBL] [Abstract][Full Text] [Related]
5. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
[TBL] [Abstract][Full Text] [Related]
6. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.
Hanley AJ; Zinman B; Sheridan P; Yusuf S; Gerstein HC;
Diabetes Care; 2010 Mar; 33(3):608-13. PubMed ID: 20009095
[TBL] [Abstract][Full Text] [Related]
7. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S
Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075
[TBL] [Abstract][Full Text] [Related]
8. Effect of ramipril on the incidence of diabetes.
; Bosch J; Yusuf S; Gerstein HC; Pogue J; Sheridan P; Dagenais G; Diaz R; Avezum A; Lanas F; Probstfield J; Fodor G; Holman RR
N Engl J Med; 2006 Oct; 355(15):1551-62. PubMed ID: 16980380
[TBL] [Abstract][Full Text] [Related]
9. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
[TBL] [Abstract][Full Text] [Related]
10. Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.
Punthakee Z; Alméras N; Després JP; Dagenais GR; Anand SS; Hunt DL; Sharma AM; Jung H; Yusuf S; Gerstein HC
Diabet Med; 2014 Sep; 31(9):1086-92. PubMed ID: 24890138
[TBL] [Abstract][Full Text] [Related]
11. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.
Regensteiner JG; Bauer TA; Reusch JE
Diabetes Care; 2005 Dec; 28(12):2877-83. PubMed ID: 16306548
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
Gerstein HC; Yusuf S; Holman R; Bosch J; Pogue J;
Diabetologia; 2004 Sep; 47(9):1519-27. PubMed ID: 15322749
[TBL] [Abstract][Full Text] [Related]
14. Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
Zinman B; Harris SB; Gerstein HC; Young TK; Raboud JM; Neuman J; Hanley AJ
Diabetes Obes Metab; 2006 Sep; 8(5):531-7. PubMed ID: 16918588
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
16. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
Juhl CB; Hollingdal M; Pørksen N; Prange A; Lönnqvist F; Schmitz O
J Clin Endocrinol Metab; 2003 Aug; 88(8):3794-800. PubMed ID: 12915671
[TBL] [Abstract][Full Text] [Related]
17. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
18. Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes.
Kulenović I
Med Arh; 2006; 60(3):179-81. PubMed ID: 16719233
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Durbin RJ
Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
[TBL] [Abstract][Full Text] [Related]
20. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
